Trial Profile
Phase I/II Clinical Study, Double Blinded, Multicentric, Controlled Against Placebo, in Parallel Groups, to Evaluate the Efficacy and Safety of a Topical Product Containing Ranpirnase in Genital Warts - HPV
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Jun 2018
Price :
$35
*
At a glance
- Drugs Ranpirnase (Primary)
- Indications Genital warts
- Focus Therapeutic Use
- Sponsors Tamir Biotechnology
- 04 Mar 2017 Results presented at the 2017 American Academy of Dermatology late-breaking research session, according to a Tamir Biotechnology media release.
- 04 Mar 2017 Results published in a Tamir Biotechnology media release.
- 04 Mar 2017 Primary endpoint (Size of lesions) has been met, according to a Tamir Biotechnology media release.